Platelet-boosting drug for solid tumor patients with low platelets
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You received cancer treatment (chemotherapy, targeted therapy, or immunotherapy) in the last 14 days
- Your platelet count has been below 75 on two separate tests, taken more than 24 hours apart, within the last 3 days
- You have not used similar platelet-raising drugs before
- You do not have a history of blood cancers like leukemia or lymphoma
- You do not have serious liver problems or a history of blood clots that require blood thinners
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new version of a platelet-boosting medicine (romiplostim) for people whose platelets drop during cancer treatment. The goal is to see if it can safely raise platelet counts so you can continue your therapy.
This trial tests a new combination of two medicines (hetrombopag and rhTPO) that help raise platelet counts, which often drop during cancer treatment. The goal is to see if this approach works well and is safe for people with low platelets caused by cancer therapy.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial tests whether giving a medicine called rhTPO early can help prevent low blood platelets, a common side effect of the chemotherapy used to prepare your body for a stem cell transplant. The goal is to help you recover faster and reduce the need for platelet transfusions.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
Hear when a new CTIT-Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.